Teleflex (NYSE:TFX) Announces Earnings Results

Teleflex (NYSE:TFX) announced its quarterly earnings data on Thursday. The medical technology company reported $2.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.90 by $0.73, FiscalAI reports. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The firm had revenue of $567.80 million for the quarter, compared to analysts’ expectations of $565.52 million. During the same period last year, the firm earned $3.67 earnings per share. The business’s revenue for the quarter was up .1% on a year-over-year basis.

Here are the key takeaways from Teleflex’s conference call:

• Teleflex reported 3.0% pro forma adjusted constant-currency revenue growth and adjusted EPS of $2.63, up 39.2% year over year. It raised 2026 adjusted EPS guidance to $7.50–$7.75 while maintaining revenue growth guidance of 3.5%–4.5%; the EPS outlook includes a $0.31 benefit from tariff refunds.
• Vascular and Surgical delivered solid growth of 4.6% and 5.1%, respectively, while Interventional returned to slight growth at 0.2%. Interventional remains affected by integration disruptions, though management reported progress in customer conversions, distributor transitions, and filling sales vacancies and expects gradual improvement.
• The Acute Care and Interventional Urology divestiture remains subject to an FTC review following a Second Request, and its closing could slip from the targeted year-end timing into 2027. Teleflex said it remains confident in completing the transaction but acknowledged that the timing is outside its control.
• Management expects a stronger financial profile in 2027, including operating margins of approximately 23% in the first year after the divestiture closes and lower interest expense and share count from debt reduction and buybacks. These improvements depend in part on completing the transaction and executing cost-saving and stranded-cost mitigation plans.
• Teleflex sees EZPLAZ as a long-term opportunity with a U.S. market potential of at least $200 million, but expects immaterial revenue in 2026 and a contribution in 2027 as it builds the market and scales production. The company also highlighted progress on its Freesolve scaffold trials and increased R&D investment, while noting that the product’s data readout is still expected in late 2027.

Teleflex Trading Down 0.8%

NYSE TFX traded down $1.26 during trading on Friday, reaching $150.89. 948,142 shares of the stock traded hands, compared to its average volume of 718,324. The firm has a market cap of $6.39 billion, a price-to-earnings ratio of 18.33, a price-to-earnings-growth ratio of 0.94 and a beta of 0.85. The stock’s 50-day moving average price is $132.15 and its 200 day moving average price is $126.09. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $156.67.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Investors of record on Monday, November 16th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Monday, November 16th. This represents a $1.36 annualized dividend and a yield of 0.9%. Teleflex’s dividend payout ratio (DPR) is presently -5.84%.

Key Headlines Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Royal Bank of Canada raised its price target to $175 from $155 and maintained an “outperform” rating, implying about 16% upside from the cited share price. Royal Bank of Canada rating
• Positive Sentiment: Wells Fargo increased its target to $167 from $138, while keeping an “equal weight” rating. Mizuho also raised its target, to $160. Wells Fargo rating Mizuho price target
• Positive Sentiment: Adjusted third-quarter EPS of $2.63 topped analyst estimates of about $1.90. Revenue of $567.8 million also narrowly exceeded expectations. Third-quarter results and outlook
• Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, equivalent to $1.36 annually and a yield of about 0.9%. Dividend announcement
• Negative Sentiment: Revenue grew only 0.2% year over year, and adjusted EPS fell from $3.67 a year earlier. The modest reported growth may limit enthusiasm despite the earnings beat. Third-quarter results and outlook

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Bank of America raised Teleflex from a “neutral” rating to a “buy” rating and increased their price target for the company from $145.00 to $158.00 in a research note on Monday, September 28th. UBS Group lifted their price objective on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Wall Street Zen raised Teleflex from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank Of Canada upped their price objective on Teleflex from $155.00 to $175.00 and gave the company an “outperform” rating in a report on Friday. Finally, Wells Fargo & Company increased their target price on Teleflex from $138.00 to $167.00 and gave the company an “equal weight” rating in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Teleflex presently has a consensus rating of “Moderate Buy” and an average target price of $160.80.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.